$0.69 EPS Expected for Kemper (KMPR); Clough Capital Partners LP Lifted Its Clovis Oncology (CLVS) Position

April 17, 2018 - By Winifred Garcia

Kemper Corporation (NYSE:KMPR) Logo

Analysts expect Kemper Corporation (NYSE:KMPR) to report $0.69 EPS on April, 30 before the open.They anticipate $0.77 EPS change or 962.50% from last quarter’s $-0.08 EPS. KMPR’s profit would be $35.51 million giving it 21.05 P/E if the $0.69 EPS is correct. After having $0.45 EPS previously, Kemper Corporation’s analysts see 53.33% EPS growth. The stock increased 1.04% or $0.6 during the last trading session, reaching $58.1. About 255,376 shares traded. Kemper Corporation (NYSE:KMPR) has risen 42.29% since April 17, 2017 and is uptrending. It has outperformed by 30.74% the S&P500.

Clough Capital Partners LP increased Clovis Oncology Inc (CLVS) stake by 83.6% reported in 2017Q4 SEC filing. Clough Capital Partners LP acquired 70,000 shares as Clovis Oncology Inc (CLVS)’s stock declined 18.56%. The Clough Capital Partners LP holds 153,735 shares with $10.45 million value, up from 83,735 last quarter. Clovis Oncology Inc now has $2.75B valuation. The stock decreased 10.27% or $6.23 during the last trading session, reaching $54.41. About 2.69 million shares traded or 108.10% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 17, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Clough Capital Partners LP decreased Cognizant Technology Solutio (NASDAQ:CTSH) stake by 99,100 shares to 229,800 valued at $16.32M in 2017Q4. It also reduced Viasat Inc (NASDAQ:VSAT) stake by 101,900 shares and now owns 393,601 shares. Logmein Inc (NASDAQ:LOGM) was reduced too.

Since December 15, 2017, it had 0 buys, and 7 selling transactions for $1.64 million activity. $192,480 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) was sold by IVERS-READ GILLIAN C. SPICKSCHEN THORLEF sold $270,000 worth of stock or 4,500 shares.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It dropped, as 35 investors sold CLVS shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported. 475 are held by Prelude Capital Limited Liability. Deutsche Natl Bank Ag holds 243,628 shares. Sg Americas Securities Llc holds 6,475 shares or 0% of its portfolio. Fmr Ltd Liability reported 2.23 million shares stake. Iguana Limited Company has 60,000 shares. Numeric Invsts Lc owns 3,400 shares or 0% of their US portfolio. Panagora Asset reported 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). C Worldwide Group A S holds 169,700 shares or 0.17% of its portfolio. Jasper Ridge Prtn Lp holds 0.04% or 9,184 shares. California-based Palo Alto Invsts Limited Liability Co has invested 9.97% in Clovis Oncology, Inc. (NASDAQ:CLVS). Glenmede Trust Co Na reported 35 shares. Qcm Cayman Ltd reported 3,672 shares. Kbc Grp Inc Nv reported 0.03% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). First Mercantile owns 1,680 shares or 0.02% of their US portfolio. Connecticut-based Aqr Cap Mngmt Limited Liability has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS).

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 64 analyst reports since September 10, 2015 according to SRatingsIntel. As per Friday, April 6, the company rating was maintained by SunTrust. The company was downgraded on Friday, February 3 by Chardan Capital Markets. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The firm earned “Outperform” rating on Thursday, February 22 by Evercore. Leerink Swann maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Monday, September 18. Leerink Swann has “Buy” rating and $107.0 target. As per Tuesday, June 20, the company rating was upgraded by Janney Capital. JP Morgan downgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, April 13 to “Neutral” rating. The stock has “Neutral” rating by Chardan Capital Markets on Monday, June 19. The firm has “Buy” rating given on Wednesday, September 21 by Stifel Nicolaus. The rating was initiated by Bank of America with “Buy” on Friday, January 27.

Investors sentiment decreased to 1.5 in Q4 2017. Its down 0.06, from 1.56 in 2017Q3. It dropped, as 11 investors sold Kemper Corporation shares while 47 reduced holdings. 35 funds opened positions while 52 raised stakes. 28.85 million shares or 1.54% less from 29.30 million shares in 2017Q3 were reported. California Pub Employees Retirement reported 0.01% of its portfolio in Kemper Corporation (NYSE:KMPR). Ny State Teachers Retirement reported 0.01% stake. State Treasurer State Of Michigan has 17,550 shares for 0.01% of their portfolio. American International owns 0.03% invested in Kemper Corporation (NYSE:KMPR) for 126,822 shares. Verition Fund Mngmt Limited Co has 0.03% invested in Kemper Corporation (NYSE:KMPR). Profund Advsrs Ltd Liability Corporation owns 7,519 shares for 0.02% of their portfolio. Stone Ridge Asset Mngmt Llc has 0.07% invested in Kemper Corporation (NYSE:KMPR) for 15,906 shares. Pacad Ltd reported 1,300 shares. Hanseatic Management reported 7,287 shares. 3.59 million were reported by Vanguard Gp Incorporated. Retail Bank Of Mellon reported 561,395 shares or 0.01% of all its holdings. 4,850 are held by Hsbc Public Ltd. Dimensional Fund Advsrs L P reported 4.32M shares. Invesco Ltd reported 66,685 shares. Geode Capital Management Ltd Company owns 392,438 shares.

Among 4 analysts covering Kemper Corp (NYSE:KMPR), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Kemper Corp had 7 analyst reports since February 18, 2016 according to SRatingsIntel. The firm earned “Hold” rating on Monday, May 9 by Sandler O’Neill. Sandler O’Neill maintained Kemper Corporation (NYSE:KMPR) rating on Friday, February 16. Sandler O’Neill has “Hold” rating and $60.0 target. The company was upgraded on Thursday, February 15 by William Blair. Janney Capital initiated the shares of KMPR in report on Tuesday, April 5 with “Buy” rating. Sandler O’Neill upgraded the stock to “Buy” rating in Thursday, February 18 report. Raymond James upgraded Kemper Corporation (NYSE:KMPR) on Thursday, August 3 to “Strong Buy” rating. The company was downgraded on Wednesday, August 10 by Janney Capital.

Kemper Corporation, a diversified insurance holding company, provides property and casualty, and life and health insurance to individuals and businesses in the United States. The company has market cap of $2.99 billion. The companyÂ’s Property & Casualty Insurance segment provides automobile, homeowners, renters, fire, umbrella, and other types of property and casualty insurance to individuals; and commercial automobile insurance to businesses. It has a 24.95 P/E ratio. This segment distributes its products through independent agents and brokers.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: